+91 8766 590 1366 sales@chemreports.com

Your Order

Home Reports

Gefitinib API Global Market

Gefitinib API Global Market

Global Gefitinib API Market Research Report 2025

This report on the global gefitinib api market research report 2025 offers a comprehensive analysis of market size, growth drivers, emerging trends, regional perform

Pages: 210

Format: PDF

Date: 12-2025

Select Licence

Description Table of Content Key Players & Segment Request for Free Sample

Global Gefitinib API Market Overview

The global Gefitinib API Market was valued at USD xxxx million in 2024 and is expected to reach USD xxxx million by 2035, growing at a CAGR of xx% during the forecast period 2025–2035. Market growth is driven by the sustained clinical relevance of gefitinib in the treatment of EGFR-mutated non-small cell lung cancer (NSCLC) and the widespread availability of generic formulations following patent expiration.

Gefitinib is a first-generation EGFR tyrosine kinase inhibitor widely prescribed in targeted oncology therapy, particularly in Asia-Pacific markets where EGFR mutation prevalence is high. The API market is characterized by strong demand from generic drug manufacturers, continuous pressure on pricing, and increasing emphasis on high-purity, regulatory-compliant production. Advancements in synthesis efficiency, impurity profiling, and supply chain reliability are shaping competitive positioning among API suppliers.

Impact of COVID-19 on the Gefitinib API Market

The COVID-19 pandemic caused short-term disruptions in API manufacturing, logistics, and raw material sourcing due to lockdowns and transportation constraints. However, demand for gefitinib APIs remained relatively stable, as oncology treatments were prioritized by healthcare systems worldwide. Post-pandemic recovery has been supported by normalization of pharmaceutical supply chains, increased generic drug utilization, and renewed focus on uninterrupted cancer care.

Market Segmentation Analysis

By Type

Purity ≥ 98%
This segment caters primarily to cost-sensitive generic formulations, particularly in emerging markets. APIs with ≥98% purity are widely accepted where regulatory frameworks allow flexibility without compromising therapeutic efficacy.

Purity ≥ 99%
High-purity gefitinib APIs are increasingly favored in regulated markets due to stringent impurity and quality standards. This segment is expected to witness comparatively faster growth, driven by exports to North America, Europe, and Japan.

By Application

Gefitinib Tablets
Tablets represent the dominant application segment, supported by the widespread clinical use of oral gefitinib formulations and strong generic penetration. Stable prescription volumes ensure consistent API demand.

Others
This segment includes alternative dosage forms, combination therapy development, and research applications. While smaller in volume, it benefits from ongoing oncology research and formulation innovation.

Key Players Analysis

The Gefitinib API market is moderately competitive, with manufacturers focusing on regulatory compliance, cost efficiency, and long-term supply contracts with formulators.

  • Scion Pharm Taiwan
    Supplies oncology APIs with a focus on quality and regional partnerships.
  • Nischem International
    Specializes in oncology and high-value APIs with export-oriented operations.
  • Jeil Pharmaceutical
    Active in oncology APIs and finished dosage forms with strong compliance capabilities.
  • Farmhispania Group
    A well-established European API supplier emphasizing high-quality oncology and specialty APIs.
  • Brawn Laboratories
    Provides cost-competitive oncology APIs and formulations for global markets.
  • Chem Genix
    Focuses on generic APIs and intermediates with flexible manufacturing capabilities.
  • Qilu Pharmaceutical
    A major producer of oncology APIs and formulations with large-scale manufacturing capacity.
  • Cipla
    A global leader in generic oncology drugs with integrated API and formulation capabilities.
  • Zhuhai Rundu Pharma
    Supplies specialty APIs with growing emphasis on anticancer molecules.
  • Zhejiang Hisun Pharmaceutical
    Known for regulatory-compliant API production and strong export presence.

Regional Analysis

North America

North America represents a high-value market driven by strong demand for targeted oncology therapies and stringent regulatory standards. Imports of high-purity gefitinib APIs support generic drug manufacturing.

Europe

Europe shows steady growth, supported by well-established oncology treatment protocols, high generic penetration, and strict quality requirements favoring compliant API suppliers.

Asia-Pacific

Asia-Pacific dominates global gefitinib API production and consumption, led by China and India. High NSCLC incidence, early adoption of EGFR inhibitors, and cost-efficient manufacturing infrastructure drive regional leadership.

South America

The South American market is expanding gradually, supported by improving access to oncology treatments and increasing use of affordable generics.

Middle East & Africa

This region exhibits moderate growth, driven by expanding healthcare infrastructure, rising cancer diagnosis rates, and increased imports of generic oncology medicines.

DRTO Analysis (Drivers, Restraints, Trends & Opportunities)

Drivers

  • Rising global incidence of EGFR-mutated non-small cell lung cancer (NSCLC), particularly in Asia-Pacific.
  • Continued clinical use of first-generation EGFR inhibitors due to cost advantages over newer therapies.
  • Patent expiry enabling widespread generic Gefitinib formulations.
  • Growing access to oncology drugs in emerging economies through public health programs.
  • Expansion of API manufacturing capacity in China and India.

Restraints

  • Strong pricing pressure caused by high generic competition.
  • Gradual therapeutic shift toward newer-generation EGFR inhibitors in some markets.
  • Stringent regulatory and impurity-control requirements for oncology APIs.
  • Dependence on oncology prescription patterns and treatment guidelines.

Trends

  • Increasing preference for high-purity (≥99%) Gefitinib APIs in regulated markets.
  • Emphasis on process optimization and cost reduction to protect margins.
  • Greater use of long-term supply contracts between API producers and formulators.
  • Diversification of sourcing strategies by pharmaceutical companies to ensure supply security.

Opportunities

  • Sustained demand in cost-sensitive markets where Gefitinib remains first-line therapy.
  • Growth in exports of compliant APIs to the US, EU, and Japan.
  • Rising demand for second-source API suppliers among global formulators.
  • Expansion into adjacent oncology APIs using similar synthesis capabilities.

SWOT Analysis for Key Players

Strengths

  • Strong expertise in oncology API synthesis and scale-up.
  • Established regulatory compliance and audit experience.
  • Cost-efficient manufacturing, particularly in Asia.
  • Long-term relationships with generic drug manufacturers.

Weaknesses

  • High exposure to commoditization and price erosion.
  • Limited differentiation among standard-grade API suppliers.
  • Dependence on a narrow oncology product portfolio for some manufacturers.

Opportunities

  • Expansion into regulated markets with high-purity offerings.
  • Portfolio diversification into other EGFR inhibitors and oncology APIs.
  • Strategic partnerships with finished-dosage manufacturers.
  • Increased demand from government-funded cancer treatment programs.

Threats

  • Declining prescriptions due to adoption of newer targeted therapies.
  • Regulatory actions affecting facility approvals or exports.
  • Aggressive competition from low-cost manufacturers.
  • Supply chain disruptions for key chemical intermediates.

Porter’s Five Forces Analysis

Threat of New Entrants – Low to Moderate

High regulatory barriers, technical complexity, and compliance costs limit rapid new entry.

Bargaining Power of Suppliers – Moderate

Specialized intermediates provide suppliers some leverage, partially offset by backward integration.

Bargaining Power of Buyers – High

Large pharmaceutical buyers exert strong pressure on price, quality, and delivery timelines.

Threat of Substitutes – Moderate

Newer EGFR inhibitors and alternative targeted therapies pose medium-term substitution risk.

Competitive Rivalry – High

Intense competition driven by pricing, regulatory compliance, and manufacturing efficiency.

Competitive Landscape Matrix

Company

API Quality

Regulatory Strength

Cost Competitiveness

Strategic Focus

Cipla

Very High

Very High

Medium

Integrated oncology generics

Qilu Pharmaceutical

High

High

High

Large-scale oncology APIs

Zhejiang Hisun Pharmaceutical

Very High

Very High

Medium

Regulated-market APIs

Farmhispania Group

Very High

Very High

Medium

Specialty oncology APIs

Jeil Pharmaceutical

High

High

Medium

Oncology APIs & formulations

Brawn Laboratories

Medium

Medium

High

Cost-efficient generics

Scion Pharm Taiwan

High

Medium

Medium

Specialty API supply

Zhuhai Rundu Pharma

Medium

Medium

High

Export-oriented oncology APIs

Investor-Focused Executive Summary

The Global Gefitinib API Market is a mature and highly competitive segment within the oncology pharmaceutical supply chain. Demand is sustained by the continued clinical relevance of Gefitinib in EGFR-mutated NSCLC, particularly in emerging and cost-sensitive markets. While newer therapies are gaining traction, Gefitinib remains a widely prescribed and affordable treatment option, ensuring ongoing API demand.

Asia-Pacific dominates production and consumption due to manufacturing scale and disease prevalence, while North America and Europe remain important high-value markets driven by regulatory compliance and generic penetration. Competitive intensity is high, with pricing pressure balanced by opportunities in high-purity APIs and regulated-market exports.

From an investment perspective, the market offers stable, volume-driven returns with moderate margins. Companies that combine regulatory credibility, cost efficiency, and diversified oncology portfolios are best positioned to maintain profitability amid ongoing generic competition.

 

1. Market Overview of Gefitinib API Market
    1.1 Gefitinib API Market Market Overview
        1.1.1 Gefitinib API Market Product Scope
        1.1.2 Market Status and Outlook
    1.2 Gefitinib API Market Market Size by Regions:
    1.3 Gefitinib API Market Historic Market Size by Regions
    1.4 Gefitinib API Market Forecasted Market Size by Regions
    1.5 Covid-19 Impact on Key Regions, Keyword Market Size YoY Growth
        1.5.1 North America
        1.5.2 East Asia
        1.5.3 Europe
        1.5.4 South Asia
        1.5.5 Southeast Asia
        1.5.6 Middle East
        1.5.7 Africa
        1.5.8 Oceania
        1.5.9 South America
        1.5.10 Rest of the World
    1.6 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
        1.6.1 Covid-19 Impact: Global GDP Growth,  Projections
        1.6.2 Covid-19 Impact: Commodity Prices Indices
        1.6.3 Covid-19 Impact: Global Major Government Policy
2. Covid-19 Impact Gefitinib API Market Sales Market by Type
    2.1 Global Gefitinib API Market Historic Market Size by Type
    2.2 Global Gefitinib API Market Forecasted Market Size by Type
    2.3 Purity ? 98 %
    2.4 Purity ? 99 %
3. Covid-19 Impact Gefitinib API Market Sales Market by Application
    3.1 Global Gefitinib API Market Historic Market Size by Application
    3.2 Global Gefitinib API Market Forecasted Market Size by Application
    3.3 Gefitinib Tablets
    3.4 Others
4. Covid-19 Impact Market Competition by Manufacturers
    4.1 Global Gefitinib API Market Production Capacity Market Share by Manufacturers
    4.2 Global Gefitinib API Market Revenue Market Share by Manufacturers
    4.3 Global Gefitinib API Market Average Price by Manufacturers
5. Company Profiles and Key Figures in Gefitinib API Market Business
    5.1 Scion Pharm Taiwan
        5.1.1 Scion Pharm Taiwan Company Profile
        5.1.2 Scion Pharm Taiwan Gefitinib API Market Product Specification
        5.1.3 Scion Pharm Taiwan Gefitinib API Market Production Capacity, Revenue, Price and Gross Margin
    5.2 Nischem International
        5.2.1 Nischem International Company Profile
        5.2.2 Nischem International Gefitinib API Market Product Specification
        5.2.3 Nischem International Gefitinib API Market Production Capacity, Revenue, Price and Gross Margin
    5.3 Jeil Pharmaceutical
        5.3.1 Jeil Pharmaceutical Company Profile
        5.3.2 Jeil Pharmaceutical Gefitinib API Market Product Specification
        5.3.3 Jeil Pharmaceutical Gefitinib API Market Production Capacity, Revenue, Price and Gross Margin
    5.4 Farmhispania Group
        5.4.1 Farmhispania Group Company Profile
        5.4.2 Farmhispania Group Gefitinib API Market Product Specification
        5.4.3 Farmhispania Group Gefitinib API Market Production Capacity, Revenue, Price and Gross Margin
    5.5 Brawn Laboratories
        5.5.1 Brawn Laboratories Company Profile
        5.5.2 Brawn Laboratories Gefitinib API Market Product Specification
        5.5.3 Brawn Laboratories Gefitinib API Market Production Capacity, Revenue, Price and Gross Margin
    5.6 Chem Genix
        5.6.1 Chem Genix Company Profile
        5.6.2 Chem Genix Gefitinib API Market Product Specification
        5.6.3 Chem Genix Gefitinib API Market Production Capacity, Revenue, Price and Gross Margin
    5.7 Qilu Pharmaceutial
        5.7.1 Qilu Pharmaceutial Company Profile
        5.7.2 Qilu Pharmaceutial Gefitinib API Market Product Specification
        5.7.3 Qilu Pharmaceutial Gefitinib API Market Production Capacity, Revenue, Price and Gross Margin
    5.8 Cipla
        5.8.1 Cipla Company Profile
        5.8.2 Cipla Gefitinib API Market Product Specification
        5.8.3 Cipla Gefitinib API Market Production Capacity, Revenue, Price and Gross Margin
    5.9 Zhuhai Rundu Pharma
        5.9.1 Zhuhai Rundu Pharma Company Profile
        5.9.2 Zhuhai Rundu Pharma Gefitinib API Market Product Specification
        5.9.3 Zhuhai Rundu Pharma Gefitinib API Market Production Capacity, Revenue, Price and Gross Margin
    5.10 Zhejiang Hisun Pharmaceutical
        5.10.1 Zhejiang Hisun Pharmaceutical Company Profile
        5.10.2 Zhejiang Hisun Pharmaceutical Gefitinib API Market Product Specification
        5.10.3 Zhejiang Hisun Pharmaceutical Gefitinib API Market Production Capacity, Revenue, Price and Gross Margin
6. North America
    6.1 North America Gefitinib API Market Market Size
    6.2 North America Gefitinib API Market Key Players in North America
    6.3 North America Gefitinib API Market Market Size by Type
    6.4 North America Gefitinib API Market Market Size by Application
7. East Asia
    7.1 East Asia Gefitinib API Market Market Size
    7.2 East Asia Gefitinib API Market Key Players in North America
    7.3 East Asia Gefitinib API Market Market Size by Type
    7.4 East Asia Gefitinib API Market Market Size by Application
8. Europe
    8.1 Europe Gefitinib API Market Market Size
    8.2 Europe Gefitinib API Market Key Players in North America
    8.3 Europe Gefitinib API Market Market Size by Type
    8.4 Europe Gefitinib API Market Market Size by Application
9. South Asia
    9.1 South Asia Gefitinib API Market Market Size
    9.2 South Asia Gefitinib API Market Key Players in North America
    9.3 South Asia Gefitinib API Market Market Size by Type
    9.4 South Asia Gefitinib API Market Market Size by Application
10. Southeast Asia
    10.1 Southeast Asia Gefitinib API Market Market Size
    10.2 Southeast Asia Gefitinib API Market Key Players in North America
    10.3 Southeast Asia Gefitinib API Market Market Size by Type
    10.4 Southeast Asia Gefitinib API Market Market Size by Application
11. Middle East
    11.1 Middle East Gefitinib API Market Market Size
    11.2 Middle East Gefitinib API Market Key Players in North America
    11.3 Middle East Gefitinib API Market Market Size by Type
    11.4 Middle East Gefitinib API Market Market Size by Application
12. Africa
    12.1 Africa Gefitinib API Market Market Size
    12.2 Africa Gefitinib API Market Key Players in North America
    12.3 Africa Gefitinib API Market Market Size by Type
    12.4 Africa Gefitinib API Market Market Size by Application
13. Oceania
    13.1 Oceania Gefitinib API Market Market Size
    13.2 Oceania Gefitinib API Market Key Players in North America
    13.3 Oceania Gefitinib API Market Market Size by Type
    13.4 Oceania Gefitinib API Market Market Size by Application
14. South America
    14.1 South America Gefitinib API Market Market Size
    14.2 South America Gefitinib API Market Key Players in North America
    14.3 South America Gefitinib API Market Market Size by Type
    14.4 South America Gefitinib API Market Market Size by Application
15. Rest of the World
    15.1 Rest of the World Gefitinib API Market Market Size
    15.2 Rest of the World Gefitinib API Market Key Players in North America
    15.3 Rest of the World Gefitinib API Market Market Size by Type
    15.4 Rest of the World Gefitinib API Market Market Size by Application
16 Gefitinib API Market Market Dynamics
    16.1 Covid-19 Impact Market Top Trends
    16.2 Covid-19 Impact Market Drivers
    16.3 Covid-19 Impact Market Challenges
    16.4 Porter?s Five Forces Analysis
18 Regulatory Information
17 Analyst's Viewpoints/Conclusions
18 Appendix
    18.1 Research Methodology
        18.1.1 Methodology/Research Approach
        18.1.2 Data Source
    18.2 Disclaimer

Market Segmentation Analysis

By Type

Purity ≥ 98%
This segment caters primarily to cost-sensitive generic formulations, particularly in emerging markets. APIs with ≥98% purity are widely accepted where regulatory frameworks allow flexibility without compromising therapeutic efficacy.

Purity ≥ 99%
High-purity gefitinib APIs are increasingly favored in regulated markets due to stringent impurity and quality standards. This segment is expected to witness comparatively faster growth, driven by exports to North America, Europe, and Japan.

By Application

Gefitinib Tablets
Tablets represent the dominant application segment, supported by the widespread clinical use of oral gefitinib formulations and strong generic penetration. Stable prescription volumes ensure consistent API demand.

Others
This segment includes alternative dosage forms, combination therapy development, and research applications. While smaller in volume, it benefits from ongoing oncology research and formulation innovation.

Key Players Analysis

The Gefitinib API market is moderately competitive, with manufacturers focusing on regulatory compliance, cost efficiency, and long-term supply contracts with formulators.

  • Scion Pharm Taiwan
    Supplies oncology APIs with a focus on quality and regional partnerships.
  • Nischem International
    Specializes in oncology and high-value APIs with export-oriented operations.
  • Jeil Pharmaceutical
    Active in oncology APIs and finished dosage forms with strong compliance capabilities.
  • Farmhispania Group
    A well-established European API supplier emphasizing high-quality oncology and specialty APIs.
  • Brawn Laboratories
    Provides cost-competitive oncology APIs and formulations for global markets.
  • Chem Genix
    Focuses on generic APIs and intermediates with flexible manufacturing capabilities.
  • Qilu Pharmaceutical
    A major producer of oncology APIs and formulations with large-scale manufacturing capacity.
  • Cipla
    A global leader in generic oncology drugs with integrated API and formulation capabilities.
  • Zhuhai Rundu Pharma
    Supplies specialty APIs with growing emphasis on anticancer molecules.
  • Zhejiang Hisun Pharmaceutical
    Known for regulatory-compliant API production and strong export presence.

Upto 24 to 48 hrs (Working Hours)

Upto 72 hrs max (Working Hours) - Weekends and Public Holidays

Single User License - Allows access to only one person to the report.

Multi User License - Allows sharing with max 5 persons within organization.

Corporate License – Can be shared across entire organization.

Online Payments with PayPal

Wire Transfer / Bank Transfer

Why Choose Us

24/7 Expert Support

At ChemReports, we understand that business decisions can’t wait. Our research specialists are available anytime to answer your queries and guide you through our reports, ensuring quick and reliable assistance.

Comprehensive Market Coverage

ChemReports provides 360° market analysis across materials, technologies, and global chemical sectors—helping you make confident business decisions.

Actionable Intelligence

We turn complex data into strategic insights to support fact-based decisions, market entry strategies, and competitive analysis.

Data Privacy & Security

Your personal and business information is completely secure with us. We value your trust and ensure strict confidentiality.

Customized Research

Need tailored insights? Our analysts provide custom reports built on authentic data and aligned with your specific business goals.

FAQs

Yes, we are providing all research support to get resolve all queries and concerns regarding the report. For all our clients.
Yes, we are providing complete customization in every report to fulfill your business needs.
Yes, we are providing regional and countries level analysis in the report, please mention the countries you are looking.
Yes, we are providing a discount for individuals and startups.
We offer access to more than one million market research reports. If the specific topic you need is not listed on our website, simply email us your requirements at sales@chemreports.com. Our research team will review your request and provide a customized report or the most relevant available study. We?re always happy to assist you with tailored solutions.